← board
REVB
Revelation Biosciences, Incdistress 5/10 · elevated risk$1.12-3%today-91% from 52w high
Nephrology 1
Lead: chronic kidney disease
Revenue
pre-revenue
Liquidity
$14M
Runway
1.6 yrs
Shares 1y
+130%
Price & events
-67.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-0.9%
1W
+6.7%
1M
-3.4%
3M
-56.7%
6M
-90.9%
1Y
-99.6%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $4.38M
- Volume
- 2.38K
- 52 Week Range
- $0.96 – $12.36
- Total Shares
- 3.91M
- Float Shares
- 3.44M
- Short %
- 0.37%
- % Held by Insiders
- 4.79%
- % Held by Institutions
- 12.79%
- RVOL
- 0.05x
- Beta
- -0.12
Pipeline stages · 1 programs
Intravenous Gemini
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07-22 | Phase 1/2 | Intravenous Gemini | Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | 40 | completed |
Catalyst news & presentations · 9
- 2026 timeframeGuided 40%trial initiationsecondaryPhase 2/3Gemini · Plan to start later stage clinical study in AKI during 2026SEC 8-K
- 2026-08-07earningsEarningsEarnings releaseyahoo
- 2026-01-21fda agreementGemini · FDA agreement on single adaptive Phase 2/3 study design and composite endpoint of death/dialysis for AKISEC 8-K
- first half of 2025trial initiationsecondaryPhase 1Gemini · Initiation of Phase 1b clinical study in chronic kidney patientsSEC 8-K
- mid-year 2025readoutPhase 1Gemini · Topline data including safety, tolerability, and biomarkers of target activity expected.SEC 8-K
- 1st half 2025readoutPhase 1GEM-CKD · Topline data from PRIME Phase 1b studySEC 8-K
- January 21, 2025trial initiationsecondaryPhase 1Gemini · Commencement of PRIME Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 CKD.SEC 8-K
- Jan 2025trial initiationsecondaryPhase 1GEM-CKD · PRIME Phase 1b study in Stage 3/4 CKD patients initiatedSEC 8-K
- 2024-12-02fda agreementGemini · FDA acceptance of Gemini INDSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 3,908,420 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — chronic kidney disease
- LLYELI LILLY & Co$1094.4B · D3
- IRONDisc Medicine, Inc.$2.8B · D1
- MLYSMineralys Therapeutics, Inc.$2.1B · D6
- AKBAAkebia Therapeutics, Inc.$329M · D0
- UNCYUnicycive Therapeutics, Inc.$147M · D6
- REVBWREVELATION BIOSCIENCES, INC.$33,222 · D6
- BAYRY— · D2
- AZNASTRAZENECA PLC— · D3
- NONOFNOVO NORDISK A S— · D2
- PROKPROKIDNEY CORP.— · D5
Recent news
- 2026-07-21Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weatherford Democrat
- 2026-07-21Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
- 2026-07-21Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Newswire.com
- 2026-07-21Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
- 2026-07-14Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
- 2026-07-13Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
- 2026-07-10Revelation Biosciences Announces Adoption of Stockholder Rights Plan - ACCESS Newswire
- 2026-07-10New plan lets Revelation investors buy discounted shares if a buyer crosses 10% - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.